Severe Heart Failure Treatment: FineHeart Completes its Series B Funding Taking the Total to €21 Million
€6 million of further funds raised in addition to the €15 million in June Clinical trials expected in 2022 FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER
Source: finanznachrichten.de